An Observational Follow-up Study of 1st-Line Treatment With Herceptin (Trastuzumab) in Patients With Metastatic Breast Cancer (Post-HERMINE)
NCT01332981 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 220
Last updated 2016-02-22
Summary
This is an observational follow-up study on the efficacy of 1st-line treatment with Herceptin (trastuzumab) in patients with metastatic breast cancer 7 years after initiation of treatment.
Conditions
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Clinical Trials · Hoffmann-La Roche
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2010-02-28
- Primary Completion
- 2010-10-31
- Completion
- 2010-10-31
Countries
- France
Study Locations
More Related Trials
-
A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer
NCT00475670 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Herceptin (Trastuzumab) in Combination With 2nd-Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.
NCT00444587 ·Status: COMPLETED ·Phase: PHASE2
-
Observational Study of Pertuzumab Safety in Participants With Breast Cancer
NCT02266173 ·Status: COMPLETED
-
A Study of Herceptin (Trastuzumab)and Biomarkers in Patients With HER2-Positive Metastatic Breast Cancer
NCT00885755 ·Status: COMPLETED ·Phase: PHASE2
-
Intrathecal Trastuzumab Administration in Metastatic Breast Cancer Patients Developing Carcinomatous Meningitis
NCT01373710 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function
NCT01513083 ·Status: COMPLETED ·Phase: PHASE1
-
Safety And Efficacy Study Of The Combination Of CpG 7909 And Herceptin In Patients With Metastatic Breast Cancer
NCT00031278 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Trastuzumab Optimization Trial in Breast Cancer
NCT00637325 ·Status: UNKNOWN ·Phase: PHASE3
-
A Study of Herceptin (Trastuzumab) in Combination With Xeloda (Capecitabine) in Patients With Metastatic or Recurrent HER2-positive Breast Cancer After First-Line or (Neo)Adjuvant Therapy.
NCT01290718 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer
NCT01491737 ·Status: COMPLETED ·Phase: PHASE2
-
Novel Capecitabine Dosing Schedule in Combination With Lapatinib, Based on the Norton-Simon Mathematical Method in Patients With HER2 Overexpressed/Amplified, Trastuzumab (Herceptin) -Refractory, Metastatic Breast Cancer
NCT00721630 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment
NCT01702571 ·Status: COMPLETED ·Phase: PHASE3
-
Trastuzumab and Gefitinib in Treating Patients With Metastatic Breast Cancer
NCT00024154 ·Status: COMPLETED ·Phase: PHASE2
-
Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/Neu Overexpression
NCT00033514 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Monoclonal Antibody Plus Chemotherapy in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2
NCT00019812 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Metastatic or Locally Advanced Breast Cancer
NCT02015676 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer
NCT01137994 ·Status: WITHDRAWN ·Phase: PHASE2
-
Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast Cancer
NCT06175390 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of Trastuzumab-MCC-DM1 in Patients With HER2- Positive Locally Advanced or Metastatic Breast Cancer
NCT01120561 ·Status: NO_LONGER_AVAILABLE
-
Efficacy Study of Single Agent Trastuzumab or Lapatinib to Treat HER2-Overexpressing Breast Cancer
NCT00842998 ·Status: UNKNOWN ·Phase: PHASE2
-
Evaluation of Pertuzumab-Trastuzumab and Taxane in the Standard Treatment of Metastatic Breast Cancer
NCT03979911 ·Status: UNKNOWN
-
A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer
NCT00829166 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Assess Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in Participants With Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer
NCT01565083 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer
NCT05041842 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Trial for HER2 Positive Breast Cancer Patients With Metastatic Disease
NCT00191373 ·Status: COMPLETED ·Phase: PHASE2